Compounded GLP-1 microdosing: what the literature describes
The term “microdosing” is circulating in conversations about GLP-1 therapy. Here’s what the published research actually says about dose-response — and where the evidence gets thin.
TL;DR
- “Microdosing” in the GLP-1 context typically means doses below the labeled titration schedule — not a formally defined clinical term.
- Published dose-response data from the STEP trials covers a range of 0.25 mg to 2.4 mg weekly for semaglutide; effects at sub-0.25 mg doses in humans are not well-characterized in peer-reviewed literature.
- Compounded formulations may include adjunct ingredients such as B12 or niacinamide; the clinical rationale for these additions varies by prescribing clinician and 503A pharmacy protocol.
What it is
In clinical practice, “microdosing” GLP-1 compounds refers to intentional use of doses below the standard starting dose on a branded label. For semaglutide, the approved titration starts at 0.25 mg per week as an initiation dose — a level chosen in part to minimize gastrointestinal side effects during early weeks of therapy. Sub-therapeutic microdosing goes further, using doses that fall below even that starting point. This is not a standardized protocol with a formal peer-reviewed definition; it is a clinical practice pattern that has emerged alongside compounded formulations. Compounded GLP-1 products discussed in this context are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved.
How it works
The dose-response relationship for semaglutide has been examined across the STEP trial program, which studied weekly doses from 0.25 mg through 2.4 mg. At higher doses within that range, more pronounced effects on body weight and appetite signaling were generally observed — consistent with what receptor pharmacology would predict for agonist concentration curves. Below the initiation dose, data in humans is sparse in the peer-reviewed literature. Preclinical receptor-binding research has described GLP-1 receptor dose-response curves, but translating those findings directly to human clinical outcomes is not straightforward.
Who asks about it
People come to this topic from two directions: those experiencing side effects at standard doses who are wondering whether a lower dose preserves some benefit with fewer GI symptoms, and those who have heard about compounded adjunct formulations and want to understand what’s actually in them and why. Both are reasonable clinical questions that belong in a conversation with a licensed clinician — not self-managed.
What the research says
The STEP 1 trial (Wilding et al., NEJM 2021) and related STEP publications provide the most robust dose-response data available for semaglutide in non-diabetic adults with overweight or obesity. These trials did not study microdoses. A small number of case reports and clinical practice letters in the literature describe individualized low-dose protocols, but these do not constitute controlled evidence. Some compounded formulations include adjunct ingredients — B12 (cyanocobalamin or methylcobalamin) and niacinamide are the most commonly referenced — which clinicians sometimes add with the intent of supporting tolerability or metabolic co-factors; peer-reviewed controlled data on these specific combinations in compounded GLP-1 preparations is limited as of publication.
What to know before considering it
Any GLP-1 therapy — including compounded formulations at any dose — requires a valid prescription and licensed clinician evaluation. There is no published evidence that sub-initiation-dose microdosing produces the same outcomes as studied doses. The clinical rationale, risks, and monitoring needs of any individualized dosing protocol should be established by a physician who can review your full health history. Compounded products are subject to ongoing litigation affecting the compounded GLP-1 space more broadly.
The Halftime POV
The interest in lower-dose GLP-1 approaches reflects something real: many people want to understand whether they can access some of the studied benefits with fewer of the commonly reported side effects. That’s a legitimate clinical question. The honest answer from the literature is that the data gets thinner the further you move from the studied dose range. A clinician who tells you what is known and what isn’t known on this topic is giving you more than one who just writes the prescription.
Related reading:
FAQ
Q: What is GLP-1 microdosing? A: Microdosing refers to using sub-label doses of GLP-1 receptor agonists — below the doses studied in the STEP or LEADER trials. It is used in compounded GLP-1 protocols to allow gradual dose escalation and potentially reduce side effect burden. Published dose-response literature describes a dose-dependent relationship between GLP-1 agonism and both efficacy and adverse events.
Q: Is there published data on low-dose GLP-1? A: Published dose-finding studies for semaglutide and tirzepatide examined multiple dose levels. The STEP 5 and related trial data show that lower doses produce less pronounced but still measurable effects on weight and glucose. Sub-label microdosing as practiced in compounded protocols has limited standalone trial data — it extrapolates from approved dose-response curves.
Q: Does microdosing reduce side effects? A: The dose-response relationship documented in published trials suggests that lower doses are generally associated with less nausea and gastrointestinal burden. However, data on the specific sub-label dose ranges used in compounded microdosing protocols is not available from large randomized trials. Clinical experience and published pharmacology are the current basis for protocol design.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Halftime Health is launching soon — join the waitlist to get updates.
Note on ongoing litigation: Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb. 2026). The regulatory landscape for compounded GLP-1 formulations continues to evolve.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” NEJM, 2021 (STEP 1)
- Davies M, et al. “Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2).” The Lancet, 2021
- FDA. Ozempic (semaglutide) Prescribing Information. 2023
